New biomarker data from BEXMAB study at EHA2023
Faron Pharmaceuticals Oy (“Faron” or “the Company”) Faron Announces New Biomarker Data from Phase I/II BEXMAB Study at EHA2023 Hybrid Congress · Bexmarilimab mode of action in AML/MDS supported with durable Clever-1 target engagement in bone marrow, with increases observed in T and NK cells and antigen presentation · Clinical activity across indications, with objective responses in 5 of 10 patients · Dose escalation ongoing, with initiation in 2H 2023 of Phase II in relapsed/refractory AML and MDS after failure on hypomethylating agents Press Release, June 9,